Claritev (NYSE:CTEV) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Claritev (NYSE:CTEV) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other research firms also recently commented on CTEV. Zacks Research downgraded Claritev from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Barclays began coverage on shares of Claritev in a research report on Friday, April 24th. They issued an “overweight” rating and a $28.00 price target on the stock. Piper Sandler set a $61.00 price target on shares of Claritev in a research note on Wednesday, June 3rd. Canaccord Genuity Group increased their price objective on shares of Claritev from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a research note on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Claritev currently has a consensus rating of “Hold” and an average price target of $34.50.

Claritev Price Performance

NYSE CTEV opened at $32.00 on Friday. The stock has a market capitalization of $545.60 million, a PE ratio of -1.88 and a beta of 0.74. The business has a 50 day simple moving average of $28.88 and a two-hundred day simple moving average of $23.79. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07.

Hedge Funds Weigh In On Claritev

Several large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in Claritev in the third quarter worth $1,245,000. Vanguard Group Inc. purchased a new stake in shares of Claritev in the third quarter valued at $27,483,000. Ameritas Investment Partners Inc. bought a new stake in shares of Claritev in the 3rd quarter worth about $42,000. Russell Investments Group Ltd. bought a new stake in shares of Claritev in the 3rd quarter worth about $369,000. Finally, Legal & General Group Plc purchased a new position in shares of Claritev during the 3rd quarter worth about $45,000. Institutional investors own 87.15% of the company’s stock.

Key Claritev News

Here are the key news stories impacting Claritev this week:

• Positive Sentiment: Better-than-expected quarterly performance: Claritev reported Q2 revenue of approximately $257.5 million, up 6.6% year over year. The company’s net loss narrowed to $59.2 million from $62.6 million, while adjusted EBITDA reached $155.8 million. Reported earnings also surpassed the consensus loss estimate, although published sources show differing EPS figures depending on the accounting presentation. Claritev Corporation Reports Second Quarter 2026 Results Claritev Reports Q2 Loss and Tops Revenue Estimates
• Positive Sentiment: Raised 2026 guidance: Management now expects full-year revenue of $1.0 billion to $1.02 billion and adjusted EBITDA of $610 million to $620 million. The revenue outlook is above the roughly $994.7 million analyst consensus, signaling confidence in continued operating momentum. Claritev Beats Second-Quarter Expectations and Raises Guidance
• Positive Sentiment: Improved cash generation: Operating cash flow increased to $92.7 million from $61.2 million a year earlier, while free cash flow rose to $54.6 million from $36.6 million. The gains provide additional support for the company’s financial flexibility. Claritev Q2 Revenue Rises 6.6 Percent
• Positive Sentiment: Favorable trading sentiment: Investor commentary focused on the earnings beat, higher guidance and increased trading volume. Six reported insider transactions over the past six months were purchases, with no reported sales, though insider activity is not a guarantee of future performance. Claritev Stock Opinions on Q2 Earnings Beat

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.